(Q38106905)

29 August 2017

title

EGFR tyrosine kinase inhibitors: difference in efficacy and resistance (English)

1 reference

29 August 2017

Kyle W Robinson

1

1 reference

29 August 2017

Alan B Sandler

series ordinal

2

1 reference

29 August 2017

publication date

1 August 2013

1 reference

29 August 2017

published in

Current Oncology Reports

1 reference

29 August 2017

volume

15

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

396-404

1 reference

29 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0323-7

First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23674236

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Non-small cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23674236

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23674236

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11912-013-0323-7

1 reference

Dimensions Publication ID

29 August 2017

1004356929

0 references

1 reference